124 related articles for article (PubMed ID: 1647501)
1. Pituitary hyperplasia after goserelin (LHRH-analogue) therapy.
Radner H; Pummer K; Lax S; Wandschneider G; Höfler H
Neuropathol Appl Neurobiol; 1991 Feb; 17(1):75-81. PubMed ID: 1647501
[TBL] [Abstract][Full Text] [Related]
2. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
3. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
4. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.
Petersson F; Hammar M; Mathson K; Hjertberg H; Varenhorst E
Scand J Urol Nephrol; 1987; 21(4):267-71. PubMed ID: 2965409
[TBL] [Abstract][Full Text] [Related]
5. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
Mahler C; Verhelst J; Chaban M; Denis L
Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
[TBL] [Abstract][Full Text] [Related]
6. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
Ryan PG; Peeling WB
Am J Clin Oncol; 1988; 11 Suppl 2():S169-72. PubMed ID: 2977272
[TBL] [Abstract][Full Text] [Related]
7. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
Dijkman GA; del Moral PF; Plasman JW; Kums JJ; Delaere KP; Debruyne FM; Hutchinson FJ; Furr BJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):933-6. PubMed ID: 2149507
[TBL] [Abstract][Full Text] [Related]
8. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
[TBL] [Abstract][Full Text] [Related]
9. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.
Johansen TE; Ogreid P; Kjellevold K; Blom P
Br J Urol; 1990 Apr; 65(4):376-8. PubMed ID: 2140282
[TBL] [Abstract][Full Text] [Related]
10. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
Geldof AA; de Voogt HJ; Rao BR
Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
[TBL] [Abstract][Full Text] [Related]
11. Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Chodak GW
Urology; 1989 May; 33(5 Suppl):42-4. PubMed ID: 2523610
[TBL] [Abstract][Full Text] [Related]
12. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
13. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
14. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
[No Abstract] [Full Text] [Related]
15. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
[TBL] [Abstract][Full Text] [Related]
16. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Schulze H; Senge T
J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
Furr BJ
Horm Res; 1989; 32 Suppl 1():86-92. PubMed ID: 2533160
[TBL] [Abstract][Full Text] [Related]
18. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
Peeling WB
Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
[TBL] [Abstract][Full Text] [Related]
19. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
[TBL] [Abstract][Full Text] [Related]
20. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H
Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]